These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36683291)

  • 1. Safety, Tolerability, and Pharmacokinetics of the Novel Adenosine A
    Tayama T; Ishiuchi M; Sugiyama K; Oka Y; Maeda H; Nagata Y; Hruska M; Kagawa Y
    Clin Pharmacol Drug Dev; 2023 Aug; 12(8):801-809. PubMed ID: 36683291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Shinde A; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2020 Jul; 40(7):603-615. PubMed ID: 32399853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A
    Ohno Y; Suzuki M; Asada H; Kanda T; Saki M; Miyagi H; Yasunaga M; Suno C; Iwata S; Saito JI; Uchida S
    Mol Pharmacol; 2023 Jun; 103(6):311-324. PubMed ID: 36894319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
    Nirogi R; Benade V; Goyal VK; Pandey SK; Mohammed AR; Shinde A; Dogiparti D; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2022 Sep; 42(9):747-762. PubMed ID: 35963959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study.
    Manitpisitkul P; Shalayda K; Russell L; Sanga P; Solanki B; Caruso J; Iwaki Y; Moyer JA
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):712-726. PubMed ID: 29125703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
    Seitz L; Jin L; Leleti M; Ashok D; Jeffrey J; Rieger A; Tiessen RG; Arold G; Tan JBL; Powers JP; Walters MJ; Karakunnel J
    Invest New Drugs; 2019 Aug; 37(4):711-721. PubMed ID: 30569245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-parkinsonian activity of the adenosine A
    Ohno Y; Okita E; Kawai-Uchida M; Fukuda N; Shoukei Y; Soshiroda K; Yamada K; Kanda T; Uchida S
    Eur J Pharmacol; 2023 Jul; 950():175773. PubMed ID: 37146707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
    Muehler A; Kohlhof H; Groeppel M; Vitt D
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Polasek TM; Leelasena I; Betscheider I; Marolt M; Kohlhof H; Vitt D; Fliegert F; Muehler AR
    Clin Pharmacol Drug Dev; 2023 May; 12(5):525-534. PubMed ID: 36938862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.